arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Enliven Therapeutics, Inc.

ELVN

$44.79 ▼ -2.48 (-5.25%) at close

8 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Enliven Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.5B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -20.6% ↗

FCF / Share $-1.24 ↗

Trailing P/E —

Price / Book 5.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-103.69M

↓ -16.5% —

FCF / Share Free cash flow per share

$-1.24

↑ +20.2% —

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	3.2% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	6.0% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	83.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-408.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-16.5% Weak ↑ Weak Improving Year-over-year change in net income	-24.4% Weak ↑ Weak Improving Year-over-year change in net income	-90.1% Weak ↓ Weak Declining Year-over-year change in net income	26.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-24.2% Weak Weak Year-over-year change in net income	-76.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	20.2% Good ↑ Good Improving Year-over-year change in free cash flow	9.8% Fair ↑ Fair Improving Year-over-year change in free cash flow	83.2% Excellent Excellent Year-over-year change in free cash flow	-375.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-20.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	39.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-47.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	39.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-32.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-54.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-72.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-22.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-250%)	-28.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-292%)	-29.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-294%)	49.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+227%)	-59.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-498%)	-49.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-427%)	48.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+220%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-98.90M	$-124.12M	$-100.14M	$-75.54M	$-48.31M	$-47.70M	$-4.94M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-1.83	$-1.89	$-2.01	$-12.05	$-2.37	—	—	—
Free Cash Flow per Share (USD)	$-1.24	$-1.55	$-1.72	$-10.27	$-2.16	—	—	—
Book Value per Share (USD)	$7.73	$6.33	$5.96	$-21.52	$3.27	$4.81	$-69.53	—
Tangible Book Value per Share (USD)	$7.73	$6.33	$5.96	$-21.52	$3.27	$4.81	$-69.53	—
Basic Weighted Avg Shares (shares)	56.66M	47.07M	35.55M	3.12M	21.66M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$458.31M	$302.21M	$240.26M	$68.04M	$85.49M	$84.16M	$26.43M	—
Total Equity (USD)	$459.60M	$309.85M	$245.91M	$-76.83M	$86.03M	$84.44M	$-48.85M	$-26.32M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$300.00K	$300.00K	$300.00K	$200.00K	$99.00K	$97.00K	$33.00K	—
Net Income, GAAP (USD)	$-103.69M	$-89.02M	$-71.58M	$-37.66M	$-51.38M	$-41.36M	$-23.46M	—
Operating Cash Flow (USD)	$-70.30M	$-73.19M	$-61.27M	$-32.08M	$-46.77M	$-37.40M	$-21.88M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters

Enliven Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare ELVN with peers